Drug class
Recombinant human coagulation factor VIII Fc-fusion protein (extended half-life)
Mechanism of action
Replaces deficient factor VIII in haemophilia A. Factor VIII binds von Willebrand factor in circulation; activated factor VIII acts as a cofactor for activated factor IX to convert factor X to activated factor X, restoring thrombin generation and clot formation.
General use cases
- Treatment and prophylaxis of bleeding in congenital haemophilia A (factor VIII deficiency), including routine prophylaxis and bleed control according to product-specific dosing
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
